Baseline characteristics
| Camrelizumab+apatinib 125 mg (n=3) | Camrelizumab+apatinib 250 mg (n=3) | Camrelizumab+apatinib 375 mg (n=19) | Camrelizumab+apatinib 500 mg (n=3) | All patients (n=28) | |||||||||||
| HCC (n=2) | ICC (n=1) | Total (n=3) | HCC (n=2) | ICC (n=1) | Total (n=3) | HCC (n=14) | ICC (n=5) | Total (n=19) | HCC (n=3) | ICC (n=0) | Total (n=19) | HCC (n=21) | ICC (n=7) | Total (n=28) | |
| Age (years) | 44 (35–52) | 51 (51–51) | 51 (35–52) | 58 (58–58) | 66 (66–66) | 58 (58–66) | 47 (34–64) | 58 (49–67) | 51 (34–67) | 38 (38–52) | / | 38 (38–52) | 48 (34–64) | 58 (49–67) | 52 (34–67) |
| Sex | |||||||||||||||
| Male | 2 (100) | 1 (100) | 3 (100) | 2 (100) | 1 (100) | 3 (100) | 11 (78.6) | 1 (20.0) | 12 (63.2) | 3 (100) | / | 3 (100) | 18 (85.7) | 3 (42.9) | 21 (75.0) |
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 3 (21.4) | 4 (80.0) | 7 (36.8) | 0 | / | 0 | 3 (14.3) | 4 (57.1) | 7 (25.0) |
| ECOG performance status | |||||||||||||||
| 0 | 1 (50.0) | 0 | 1 (33.3) | 0 | 0 | 0 | 7 (50.0) | 2 (40.0) | 9 (47.4) | 0 | / | 0 | 8 (38.1) | 2 (28.6) | 10 (35.7) |
| 1 | 1 (50.0) | 1 (100) | 2 (66.7) | 2 (100) | 1 (100) | 3 (100) | 7 (50.0) | 3 (60.0) | 10 (52.6) | 3 (100) | / | 3 (100) | 13 (61.9) | 5 (71.4) | 18 (64.3) |
| AFP≥400 ng/mL | 2 (100) | 0 | 2 (66.7) | 1 (50.0) | 1 (100) | 2 (66.7) | 9 (64.3) | 0 | 9 (47.4) | 2 (66.7) | / | 2 (66.7) | 14 (66.7) | 1 (14.3) | 15 (53.6) |
| BCLC stage | |||||||||||||||
| B | 0 | 0 | 0 | 0 | 0 | 0 | 3 (21.4) | 0 | 3 (15.8) | 0 | / | 0 | 3 (14.3) | 0 | 3 (10.7) |
| C | 2 (100) | 0 | 2 (66.7) | 2 (100) | 0 | 2 (66.7) | 11 (78.6) | 0 | 11 (57.9) | 3 (100) | / | 3 (100) | 18 (85.7) | 0 | 18 (64.3) |
| Extrahepatic spread | 2 (100) | 1 (100) | 3 (100) | 2 (100) | 1 (100) | 3 (100) | 13 (92.9) | 5 (100) | 18 (94.7) | 2 (66.7) | / | 2 (66.7) | 19 (90.5) | 7 (100) | 26 (92.9) |
| HBV infection | 2 (100) | 1 (100) | 3 (100) | 2 (100) | 1 (100) | 3 (100) | 12 (85.7) | 1 (20.0) | 13 (68.4) | 3 (100) | / | 3 (100) | 19 (90.5) | 3 (42.9) | 22 (78.6) |
| Child-Pugh class | |||||||||||||||
| A (5–6) | 2 (100) | 1 (100) | 3 (100) | 2 (100) | 0 | 2 (66.7) | 14 (100) | 5 (100) | 19 (100) | 2 (66.7) | / | 2 (66.7) | 20 (95.2) | 6 (85.7) | 26 (92.9) |
| B (7) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (33.3) | / | 1 (33.3) | 1 (4.8) | 0 | 1 (3.6) |
Data are shown in median (range) or n (%).
/ indicates not applicable.
AFP, alpha-petoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma.